- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc stock price live, this page displays TSX FRX stock exchange data. View the FRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Fennec Pharmaceuticals Inc real time stock price chart below.
What Is the Fennec Pharmaceuticals Inc Stock Price Today?
The Fennec Pharmaceuticals Inc stock price today is 9.880.
What Is the Stock Symbol for Fennec Pharmaceuticals Inc?
The stock symbol for Fennec Pharmaceuticals Inc is ""FRX.""
What Stock Exchange Does Fennec Pharmaceuticals Inc Trade On?
Fennec Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Fennec Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Fennec Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FRX quote. (ISIN: CA31447P1009)
What Is the Fennec Pharmaceuticals Inc Stock Price Today?
The Fennec Pharmaceuticals Inc stock price today is 9.880.
What Is the Stock Symbol for Fennec Pharmaceuticals Inc?
The stock symbol for Fennec Pharmaceuticals Inc is ""FRX.""
What Stock Exchange Does Fennec Pharmaceuticals Inc Trade On?
Fennec Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Fennec Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Fennec Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FRX quote. (ISIN: CA31447P1009)
Fair Value
An estimate of a Fennec Pharmaceuticals Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.610
9.890
52 wk Range
3.960
9.890
FENC Scorecard
Full Analysis
Net income is expected to grow this year
Trading near 52-week High
1/2
Fair Value
An estimate of a Fennec Pharmaceuticals Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.6109.890
52 wk Range
3.9609.890
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FENC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Fennec Pharmaceuticals Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
14.000
Upside
+41.70%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Fennec Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Fennec Pharma stock soars to 52-week high of $7.66
- Investing.com
- Fennec Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Fennec Pharmaceuticals Inc Company Profile
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.11 missed forecast by $0.07; revenue grew 33% YoY to $9.65M, exceeding expectations by 2.77%
- Stock dropped 17.67% in premarket trading to $7.50, reflecting investor concerns despite revenue growth
- Company targets cash profitability in H2 2025, leveraging Norgene partnership and anticipating Japan trial results in Q4
- Pedmark shows strong customer retention and new demand; management optimistic about continued growth trajectory
- Analysts maintain $13-$15 price targets; InvestingPro indicates 'GOOD' financial health despite current challenges
Last Updated: 14/08/2025, 14:30
Read Full TranscriptCompare FENC to Peers and Sector
Metrics to compare | FENC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFENCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.8x | −3.9x | −0.7x | |
PEG Ratio | 0.04 | 0.09 | 0.00 | |
Price/Book | −36.8x | 1.2x | 2.6x | |
Price / LTM Sales | 8.3x | 11.4x | 3.4x | |
Upside (Analyst Target) | 41.7% | 214.1% | 36.2% | |
Fair Value Upside | Unlock | 4.9% | 4.1% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 14.000
(+41.70% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.11 / -0.04
Revenue / Forecast
9.65M / 9.39M
People Also Watch
FAQ
What Stock Exchange Does Fennec Pharmaceuticals Inc Trade On?
Fennec Pharmaceuticals Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Fennec Pharmaceuticals Inc?
The stock symbol for Fennec Pharmaceuticals Inc is "FENC."
What Is the Fennec Pharmaceuticals Inc Market Cap?
As of today, Fennec Pharmaceuticals Inc market cap is 274.98M.
What Is Fennec Pharmaceuticals Inc's Earnings Per Share (TTM)?
The Fennec Pharmaceuticals Inc EPS (TTM) is -0.45.
When Is the Next Fennec Pharmaceuticals Inc Earnings Date?
Fennec Pharmaceuticals Inc will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is FENC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Fennec Pharmaceuticals Inc Stock Split?
Fennec Pharmaceuticals Inc has split 3 times.
How Many Employees Does Fennec Pharmaceuticals Inc Have?
Fennec Pharmaceuticals Inc has 32 employees.
What is the current trading status of Fennec Pharmaceuticals Inc (FENC)?
As of 06 Oct 2025, Fennec Pharmaceuticals Inc (FENC) is trading at a price of 9.880, with a previous close of 9.67. The stock has fluctuated within a day range of 9.610 to 9.890, while its 52-week range spans from 3.960 to 9.890.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.